

Think | Test | Treat
Because monitoring and testing matters
The think test treat programme was initiated by Incyte to raise awareness of the importance of regular and sensitive BCR-ABL1 monitoring and guidance-compliant mutation testing in patients with PH+ LEUKAEMIAS
Think
about how regular monitoring can help you identify patients
at risk and help
guide your therapeutic treatment decisions1-5
Test
CML patients with resistance/failure to current treatment, always when switching TKI, and Ph+ ALL patients with persistent or increasing MRD1,6-8
Treat
patients with resistance/failure to current treatment with the most appropriate TKI according to prior treatment and mutation testing results1,6-10
Incyte is committed to making a difference in the way the community is monitoring and performing mutation testing for patients with CML and PH+ All
INCYTE INITIATED THE THINK TEST TREAT
PROGRAMME TO:
- Identify and address barriers to optimal BCR-ABL1 monitoring and mutation testing across Europe
- Raise awareness and educate about how BCR-ABL1 monitoring and sensitive mutation testing can guide clinical decision-making in CML and Ph+ ALL